Neuroimaging for Patients With Dizziness

alexandrossfakianakis shared this article with you from Inoreader Neuroimaging for Patients With Dizziness Who Present to Outpatient Clinics vs EDs in the US Via JAMA Otolaryngology–Head & Neck Surgery Online First This cross-sectional study uses commercial and Medicare Advant age claims to characterize neuroimaging use, timing, and spending as well as the factors associated with imaging acquisition within 6 months of presentation for dizziness in outpatient clinics vs emergency departments in the US. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis

alexandrossfakianakis shared this article with you from Inoreader Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis Via Head & Neck Abstract Background Recently, randomized trials have questioned the efficacy of cetuximab-based bioradiotherapy compared to chemoradiation for patients with squamous cell carcinoma of the oropharynx, larynx, and hypopharynx (HNSCC). We compared the OS of patients treated with radiotherapy alone (RTonly), chemoradiotherapy (chemoRT), and bioradiotherapy (cetuxRT). Methods Patients with stage III–IVB HNSCC treated with RTonly, chemoRT, or cetuxRT were identified in the National Cancer Database. OS was estimated using Cox proportional hazards. Analyses were conducted on the overall cohort and propensity matched cohorts. Results 31 014 patients were treated with RTonly (22%), chemoRT (72%), or cetuxRT (6%) from 2013 to 2016. The 2-year OS was 69% for RTonly, 79% for chemoRT, and 66% for cetuxRT (p < 0.001). In the overall and propensity-matched cohorts, chemoRT and RTonly were associated with improved OS as compared to cetuxRT (p ≤ 0.001). Conclusion Compared to chemoRT or RTonly, cetuxRT is associated with decreased OS for patients with HNSCC, suggesting minimal benefit of bioradiotherapy in this population. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Inhibition of PDK1 enhances radiosensitivity and reverses epithelial–mesenchymal transition in nasopharyngeal carcinoma

alexandrossfakianakis shared this article with you from Inoreader Inhibition of PDK1 enhances radiosensitivity and reverses epithelial–mesenchymal transition in nasopharyngeal carcinoma Via Head & Neck Abstract Background Radioresistance challenges the clinical outcomes of nasopharyngeal carcinoma (NPC). The 3-phosphoinositide-dependent protein kinase 1 (PDK1) is a crucial kinase of PI3K/AKT signaling pathway which has been implicated in the process of radioresistance. However, the role of PDK1 in NPC remains largely unclear. Methods The expression of PDK1 was determined by immunohistochemistry and Western blot. The effects of RNA interference and pharmacologic inhibitor of PDK1 in combination with irradiation were investigated. Results Overexpression of PDK1 was correlated with poor prognosis in patients with NPC. PDK1 depletion enhanced radiosensitivity of NPC cells both in vitro and in vivo. Additionally, a specific PDK1 inhibitor also had the potential to enhance radiosensitivity in radioresistant NPC cells. Mechanistically, PDK1 depletion inhibited various targets of AKT including mTOR and GSK-3β and reversed the epithelial–mesenchymal transition. Conclusions These findings indicated that PDK1 might be a potential target for NPC. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Status of IDH mutations in chondrosarcoma of the jaws

alexandrossfakianakis shared this article with you from Inoreader Status of IDH mutations in chondrosarcoma of the jaws Via International Journal of Oral and Maxillofacial Surgery via MedWorm.com The aim was to analyse the relationship between mutations of the isocitrate dehydrogenase gene (IDH) and clinical characteristics of chondrosarcoma of the jaw in order to provide new information on its molecular pathology. Tissue samples were collected from 25 patients diagnosed with chondrosarcoma of the jaw. IDH mutations were detected through polymerase chain reaction and direct sequencing. Clinicopathological data were analysed retrospectively. The study included 14 female and 11 male patients; the median patient age was 38 years. (Source: International Journal of Oral and Maxillofacial Surgery) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients

alexandrossfakianakis shared this article with you from Inoreader Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients Via Journal of Clinical Pharmacy and Therapeutics Of 51 advanced lung adenocarcinoma patients with negative driver genes who received camrelizumab plus CP chemotherapy were recruited. Patients received 4 cycles of camrelizumab plus CP chemotherapy in a 21-day cycle. Then, camrelizumab, pemetrexed or camrelizumab plus pemetrexed was administered as maintenance therapy. The ORR and DCR were 58.8% and 78.4%, separately. The median PFS was 10.5 months (95%CI: 8.4–12.6 months) with 1-year PFS rate of 36.3% and 2-year PFS rate of 7.5%. Moreover, the median OS was 18.7 months (95%CI: 16.4–21.0 months) with 1-year OS rate of 79.1% and 2-year OS rate of 30.4%. Regarding safety, the commonly observed adverse events were mild and manageable. Abstract What is known and objective Camrelizumab is a recently developed PD-1 inhibitor in China applied in treating different cancers including lung cancer. This study is designed to evaluate the efficacy, safety and prognostic factors for camrelizumab plus carboplatin and pemetrexed (CP) chemotherapy in treating patients with advanced lung adenocarcinoma. Methods Of 51 advanced lung adenocarcinoma patients with negative driver genes who received camrelizumab plus CP chemotherapy were recruited. These patients received four cycles of camrelizumab plus CP chemotherapy in a 21-day cycle. Then, camrelizumab, pemetrexed or camrelizumab plus pemetrexed was administered as maintenance therapy. Results and discussion The rates of complete response, partial response, stable disease and progressive disease were 2.0%, 56.8%, 19.6% and 5.9%, respectively; while treatment response of 15.7% of patients was missing or not evaluable. The objective response and disease control rates were 58.8% and 78.4%, respectively. With a median follow-up period of 14.9 months (the follow-up duration ranged from 3.9 months to 24.3 months), 41 (83.4%) cases of disease progression and 22 (43.1%) cases of death were recorded. The median progression-free survival (PFS) was 10.5 months (95% confidence interval (CI): 8.4–12.6 months) with a 1-year PFS rate of 36.3% and a 2-year PFS rate of 7.5%. In addition, the median overall survival (OS) was 18.7 months (95% CI: 16.4–21.0 months) with a 1-year OS rate of 79.1% and a 2-year OS rate of 30.4%. In consideration of safety, the most frequent adverse events were peripheral neuropathy (37.3%), neutropenia (37.3%), alopecia (35.3%), etc. a nd most of them were grade 1–2 and could be controlled. What is new and Conclusion Camrelizumab plus CP chemotherapy achieves favourable efficacy and tolerable adverse events in advanced lung adenocarcinoma patients. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.